NEW
YORK, April 5, 2012
/PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the
Board of Directors of Allos Therapeutics, Inc. ("Allos" or the
"Company") (NASDAQ: ALTH) breached its fiduciary duty to its
shareholders in agreeing to sell Allos to Spectrum
Pharmaceuticals.
(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO
)
Under the terms of the agreement, Allos shareholders will
receive $1.82 in cash plus one
Contingent Value Right (CVR) for each share they own. This
CVR entitles Allos shareholders to an additional payment of
$0.11 per share in cash if certain
European regulatory approval and commercialization milestones for
FOLOTYN® are achieved. The investigation is focused on the
potential unfairness of the price to Allos shareholders and the
process by which the Allos Board of Directors considered and
approved the transaction.
If you are interested in discussing your rights as an Allos
stockholder, with no obligation or cost to you, please contact
Joseph R. Seidman, Jr. at:
(877) 779-1414
or
seidman@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer
and shareholder rights cases and recovered over $3 billion for its clients. It has been
named to The National Law Journal's "Plaintiffs' Hot List"
in each of the last nine years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The
law firm responsible for this advertisement is Bernstein Liebhard
LLP, 10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for
this advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
SOURCE Bernstein Liebhard LLP